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The use of cost–effectiveness as ﬁnal criterion in the reimbursement process for listing of
new pharmaceuticals can be questioned from a scientiﬁc and policy point of view. There
is a lack of consensus on main methodological issues and consequently we may question
the appropriateness of the use of cost–effectiveness data in health care decision-making.
Another concern is the appropriateness of the selection and use of an incremental cost–
effectiveness threshold (Cost/QALY). In this review, we focus mainly on only some key
methodological concerns relating to discounting, the utility concept, cost assessment, and
modeling methodologies. Finally we will consider the relevance of some other important
decision criteria, like social values and equity.
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INTRODUCTION
Escalating costs have become a major concern for healthcare pro-
fessionals, decision-makers, and the public, prompting the imple-
mentation of new cost containment measures over the last decade,
especially for new pharmaceuticals. There has been a trend toward
an increasing demand for cost–effectiveness data in the decision-
making process information in Europe (Drummond et al., 1999).
A prominent example is the assessment procedure by the National
Institute for Health and Clinical Excellence (NICE) in the United
Kingdom, but also The Netherlands, Scotland, Sweden, Belgium,
andPortugal have formal requirements for the submission of cost–
effectiveness data. Cost–effectiveness data should permit reliable,
reproducible, and veriﬁable insight into the effectiveness of a phar-
maceutical, the costs that will result from its use, and the potential
savings that will be made compared with other pharmaceuticals
and/or treatments. To do this, health economists use a measure-
ment called the “quality-adjusted life-year,” or QALY (“qually”).
The lower the ratio of a cost per QALY, the more cost–effective
a health intervention is said to be. Even though there is no the-
oretical or empirical basis for it, values ranging from $50,000 to
$100,000 are sometimes used as a threshold in the United States,
whereas in the UK, NICE has adopted a cost–effectiveness thresh-
old range of £20,000 to £30,000 per quality-adjusted life-year
(QALY) gained.
The following example illustrates the concept and also dilemma
of cost-QALY thresholds. Two cost–effectiveness studies of pre-
ventive treatment with interferon beta compared to no preventive
treatment in patients with multiple sclerosis (MS) in a British
setting were performed. The ﬁrst study by our group revealed
that interferons were much more cost–effective compared with the
results of another cost–effectiveness study (Parkin et al., 1998;Nui-
jten and Hutton, 2002). The incremental cost–effectiveness ratio
(ICER) in our study was £51,582 per QALY, while the outcomes
in the other study were £328,300 and £228,300 per QALY over
a period of 5 and 10 years respectively. Authorities with a strict
threshold of £50,000 per QALY might accept the use of inter-
ferons based on the ﬁrst study, whereas they surely would reject
the use of interferons based on the second study. The contrast-
ing cost–effectiveness outcomes in our example have far reaching
implications for patients with MS, and raise a number of funda-
mental issues regarding the use of economic evaluations by health
authorities and decision-makers.
There are several key steps when performing and interpreting
data on the economics of disease that are not part of usual patient-
oriented research practice. These include (1) deﬁning perspective
and time horizon, (2) collecting data on health care utilization,
(3) costing health care resources, (4) analyzing data on utilization
and cost, (5) deﬁning and measuring health effects, (6) adjusting
costs and effects for inﬂation and discounting, (7) and evaluating
uncertainty. The cost–effectiveness of a new intervention depends
heavily on the choices by the researcher on the above-mentioned
issues. A review of the literature shows that there is a lack of con-
sensus on main methodological issues and consequently we may
question the appropriateness of the use of cost–effectiveness data
in health care decision-making, and especially pricing and reim-
bursement decisions for new pharmaceuticals. Another concern
is the appropriateness of the selection and use of an incremen-
tal cost–effectiveness threshold (Cost/QALY). Finally a broader
concern is whether the ICER comprehends all relevant criteria
for a decision maker, for example social values and equity. In
the remainder of this review, we focus mainly on only some key
methodological concerns.
DISCOUNTING
In cost–effectiveness analysis, the valuing of costs and health
effects over time remains a controversial issue. Decisions about
the resources dedicated to prevention depend on the weight given
to future health in economic evaluations. Future costs and health
gains are commonly weighted in relation to the time at which they
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occur, future costs, and effects receiving less weight than present
ones. This procedure is called discounting.
The debate mostly focuses on whether the discount rates for
health and money should be equal and which discounting model
and time preferences are most appropriate. The majority view
is that beneﬁts and costs should be discounted at the same rate
(Gold et al., 1996). However the experts themselves admit that
the reasoning behind the use of equal discount rates for costs
and health outcomes is indeed not well developed in the pub-
lished guidance (Claxton et al., 2006). A number of authors have
suggested that the value of health grows over time and that as
a consequence the discount rate on health effects should be less
than the discount rate on costs (Brouwer et al., 2005). For example,
the current Belgian guidelines for pharmacoeconomic evaluations
recommend that future costs should be discounted at a rate of
3% and future beneﬁts at a rate of 1.5% (Cleemput et al., 2008).
Various arguments justify a different rate of discounting for health
effects than for costs. Brouwer et al. (2005) advocate discounting
future health gains at a lower rate than future costs. They dismiss
observed popular preferences for discounting health gains from
government programs at a high rate as being “implausibly high”
(Cropper et al., 1992). They also argue that people in the future
may put a higher value on their own health than people do today.
On the other hand, standard cost–effectiveness analysis for health
policies, including uniform discounting, reﬂects the moral imper-
ative to value each person’s life equally, and the political judgment
that the social beneﬁts to taxpayers of saving a poorer citizen’s life
through government action is as large as saving the life of a richer,
or future, citizen (Keeler and Weinstein, 2005). Recently, Claxton
et al. (2011) presented another argument in this debate, as they
demonstrated that if the budget for health care is ﬁxed and deci-
sions are based on ICERs, discounting costs, and health gains at
the same rate is correct only if the threshold remains constant.
The choice of discount rates can have varying effects on inter-
ventions, depending on the disease area, especially chronic disease
and preventive interventions. It is therefore crucial that appropri-
ate discount rates are used in economic evaluations. However, the
lack of consensus on one of the most sensitive variables in a health
economic study makes the case for a more restricted use of cost–
effectiveness in reimbursement decisions. The lack of consensus
is both illustrated by difference of discounting between coun-
tries as well as changes in opposite direction in revised guidelines
(UK, Netherlands, Belgium; Brouwer et al., 2005). As a conse-
quence, the reimbursement of a new pharmaceutical may vary per
country only due to the application of a different discount rate
for health outcomes leading to opposite cost–effectiveness out-
comes. This policy may be questioned from an equity perspective
within Europe, especially when the studies lead to similar cost–
effectiveness results, when applying a similar discount rate. As
a minimum, the impact of different discount rates on the over-
all cost–effectiveness results should be evaluated in a sensitivity
analysis.
THE UTILITY CONCEPT
Another methodological controversy is the utility concept. Health
effects in cost–effectiveness analysis are commonly expressed in
life-years gained, QALYs gained or lives saved. Although QALYs
are a great step forward in cost–effectiveness analysis, their use is
not straightforward. The use of QALYs does not imply that fair-
ness and equity in health care is taken into account automatically.
Second there are serious measurements problems in determining
QALYs. Several techniques are available to assign a value to a par-
ticular health state, e.g., the standard gamble, the time-trade-off,
but there is little consensus on what technique is most suitable.
The problem is that these techniques give widely different results
leading to different cost–effectiveness outcomes as recently shown
by Joree et al. (2010). In addition, the handling of time prefer-
ence may even lead to different outcomes using the same scale.
QALY values are mostly not corrected for time preference, i.e.,
a lower valuation being attached to later life-years than to ear-
lier life-years, and therefore may underestimate the true QALY
weights. Brouwer et al. (2005) showed the possible consequences
for health policymaking when they correct time-trade-off scores
for time preference, thereby taking into account severity and time
horizon (Attema and Brouwer, 2010).
Another unresolved issue is how to adjust the potential cost
per QALY threshold for the severity of the disease. For example,
in severe MS the QALY will be lower than in other chronic dis-
ease areas and hence those patients might be worse off in terms of
reimbursement decision.
In practical applications, the choice of the technique to elicit
health status values is crucial. Another unresolved issue is whose
values to take? Should the valuations of health care providers and
professionals be used? Or should preference be given to the values
of healthy people or the values of patients? Or is a random sam-
ple drawn from the general population the appropriate group?
Summarizing, the cost–effectiveness of a new pharmaceutical may
depend heavily on underlying methodological choices for mea-
surement of QALYs. As a consequence, a reimbursement decision
of a new pharmaceutical based on cost–effectiveness data can be
challenged from a scientiﬁc point of view, as long there is no
consensus on the measurement of QALYs.
COST PER QALY THRESHOLDS
Apart from the methodological inconsistencies, the interpretation
of the cost–effectiveness results of health economic evaluations
by policy-makers can also be troublesome. Partly, this is because
of the aggregated nature of the outcome of a cost–effectiveness
analysis. All economic and health aspects of the interventions are
comprised into one single ratio, the ICER. This ratio not only
encompasses aspects of monetary costs and savings, but also ele-
ments of patients’ functioning and well – being, and averted future
mortality and morbidity. From a policy maker’s point of view,
the expression of the results in a single cost–effectiveness ratio
might be attractive since it simpliﬁes the stream of information
needed for decision-making. For example, in The Netherlands,
an almost formally deﬁned threshold value for cost–effectiveness
of Ł20,000 per QALY is reported in cost–effectiveness studies (van
Lier et al., 2010). In the literature, although not undisputed, a value
of 50,000 US $ per QALY is often proposed as cost–effectiveness
threshold. The main problem with the threshold is the justiﬁca-
tion, e.g., what is the basis of the reported thresholds? Does the
threshold capture all societal preferences for selecting priorities in
the decision-making process, especially innovation?
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For example, the 50,000 US $ per QALY has been quoted for
many years as threshold in the US and was based on the dialy-
sis standard, the purported annual cost/QALY on the Medicare
program for patients with chronic renal failure (Rabinovich et al.,
2007). This study was performed in 1982, and this threshold has
never been adjusted for inﬂation, as with most internally used
thresholds. A comparison of the thresholds also shows large dif-
ferences within Europe, which cannot be explained by economic
differences. For example the threshold in The Netherlands of
Ł20,000/QALY is half of the threshold in the United Kingdom
ranging from Ł36,000 to Ł54,000. As a consequence, a new innov-
ative pharmaceutical with cost–effectiveness of Ł25,000 per QALY
might be considered not cost–effective and therefore not be reim-
bursed in The Netherlands. The same pharmaceutical might be
considered extremely cost–effective in the UK. However, it should
be noted that the threshold in The Netherlands has been raised
recently with an upper limit of Ł80,000/QALY depending on the
severity of the disease and that too much uncertainty in the ICER
alsomay lead to rejection in theUK(Busschbach andDewel,2010).
This example shows that the use of cost–effectiveness data as a
ﬁnal criterion in the reimbursement process might lead to unequal
access for innovative health care in Europe, which raises seri-
ous equity and ethical considerations. Although there are several
suggestions to set a differential threshold value between coun-
tries, associated with their relative wealth, this would not solve
the huge difference between European countries. Other propos-
als include a differential threshold value between diverse disease
and treatment characteristics, for example in The Netherlands, a
range between Ł10,00 and Ł80,000/QALY recently has been sug-
gested based on the society perspective, including indirect costs
(Busschbach and Dewel, 2010). NICE recognizes that there will
be circumstances, especially for end-of-life treatment in which it
may be appropriate to recommend the use of treatments with
high reference case ICERs (http://www.nice.org.uk/media/E4A/
79/SupplementaryAdviceTACEoL.pdf).
Adoption of a “ﬂexible threshold” approach, in which the
threshold is not the exclusive criterion for decision-making,might
resolve the previously mentioned ethical issues related to unequal
access.
QALY GAINS
Another concern is the interpretation of a QALY gain, which is
calculated by multiplying the utility gain with the number of life-
years gained. The problem is that a given number of QALYs gained,
may be the result of a prolonged survival time, utility gain, or both.
For example, a patient who has a survival gain of 4 years at a utility
level of 0.4 will result in the same 1.6 QALYs gained as a patient
with a survival gain of 2 years at a utility level of 0.8. Thus, QALYs
may be gained without additional life-years gained. The terminol-
ogy of “quality-adjusted life-years” is thus potentially confusing in
this regard. As a consequence, QALY gain is an aggregated rough
measure, which does not allow differentiation of the underlying
components (disease severity, survival). Furthermore, the QALY
gain is only useful in assessing the relative differences in outcomes
and does not give information on the absolute values, whereas
there may be a need to incorporate concerns for severity of illness
as an independent factor for societal valuations of health outcomes
(Nord et al., 1999). For example, a new treatment A may increase
the QALYs over a year from 0.1 to 0.2 leading to QALY gain of 0.1,
whereas another new treatment B may increase the QALYs over a
year from 0.8 to 0.9 leading also to QALY gain of 0.1. The relative
improvement in QALYs is much higher for treatment A (100%)
compared with treatment B (12.5%) and as a consequence a simi-
lar QALY gain may be valuated differently. Nord et al. (1999) show
how equity weights may serve to incorporate concerns for sever-
ity and potentials for health in QALY calculations. It is suggested
that the QALY as a measure of amounts of well life does not carry
sufﬁcient empirical meaning. As a measure of individuals’ per-
sonal appreciation of outcomes in their own lives the QALY does
not seem to be valid for comparisons of life-saving interventions
with interventions that improve health or increase life expectancy
(Nord, 1994).
Finally, it is important to note that there is more to health-
related quality of life than preference-based utility values. Non-
preference-baseddescriptive health-relatedquality of lifemeasures
provide unique additional value in understanding the patient’s
own viewpoint on disease and its treatment. Both generic and
disease-speciﬁc questionnaires offer the potential to assist thera-
peutic value assessment at all stages of a product’s lifecycle and to
inform medical decision-making in daily practice.
MODELING
In practice it is not always possible to derive all necessary infor-
mation from prospective randomized controlled trials. In these
cases decision-analytic models may be used to provide the nec-
essary cost–effectiveness information using various existing data
sources for clinical and economic information. Modeling studies
are based on decision analysis, which is a well-recognized method
for analyzing the consequences of decisions that are made under
uncertainty (Weinstein and Fineberg, 1980). It is an explicit, quan-
titative, prescriptive approach to healthcare decision-making and
allowsboth clinical and economic consequences of medical actions
and attitudes to be analyzed under conditions of uncertainty. From
treatment algorithms a model can be constructed which considers
the timings of actions and their consequences over time. In effect,
a model shows the consequences and complications of different
therapeutic interventions, and it should correspond as much as
possible, to the real life situation of the disease.
Projections about a pharmaceutical’s effectiveness and expected
costs canbemodeledusing realistic and explicit assumptions based
on data from clinical studies. In addition modeling often helps
overcome the practical limitations of prospective studies, partic-
ularly for chronic conditions like Parkinson’s disease that may
require longer-term extrapolations of therapeutic effects and cost
implications. Data sources for the variables being used in a model
may be meta-analysis, databases, clinical trials and/or Delphi pan-
els. The role of modeling in economic evaluationhas been explored
by discussing the concerns of models, which mainly relate to the
trade-off between internal and external validity: concerns about
the inappropriate use of clinical data, concerns in observational
data, concerns about the difﬁculties in extrapolation, concerns
about the transparency or validity of the model and the impact
of confounding variables (Nuijten, 2003). There is also the debate
over which type of model offers the most appropriate modeling
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structure. Heeg et al. (2008) provided a critical assessment of the
advantages and disadvantages of three modeling techniques using
schizophrenia as an example: decision trees, Markov models, and
discrete event simulation models. They conclude that depend-
ing on the research question, the optimal modeling approach
should be selected based on the expected differences between the
comparators, the number of co-variates, the number of patient
subgroups, the interactions between co-variates, and simulation
time (Heeg et al., 2008). As a consequence the ICER outcome of a
health economic model should be considered with prudence and
there is no guarantee that the outcome reﬂects the true cost per
QALY. The example in the beginning of this paper on the cost–
effectiveness of interferons in MS shows the variance in ICER
outcomes of two health economic models varying £51,582 per
QALY to £328,300 per QALY.
COSTS
The long list of cost categories can be divided into two discrete
resource categories: direct costs andproductivity costs.Direct costs
reﬂect the monetary burden of the medical care and non-medical
care expenditures made in response to disease. The cost of phar-
maceuticals is one type of direct medical costs. Other types of
direct medical costs include cost of hospitalizations, cost of physi-
cian visits, cost of tests and procedures, and cost of durablemedical
equipment. Direct non-medical costs include cost to caregivers or
the valued time in monetary terms in caring for a loved one. Pro-
ductivity costs reﬂect the monetary value of the work lost due to
death or morbidity induced by disease or its treatment. Therefore,
productivity cost is especially important for studies conducted
from the societal perspective.A variety of approaches for collection
of data on utilization exist, and these include subject interviews,
subject surveys, provider surveys, medical record reviews, health
care utilization diaries, and insurance claims data (Goossens et al.,
2000). Collecting data on utilization can be viewed as a detailed
accounting exercise. However, much more research is needed to
validate the accuracy of these different data collection methods.
Finally, missing utilization data can be of particular concern and
imputation or modeling methods may need to be used to evaluate
the impact of non-random missing cost information.
Costing resource units should be viewed as a research exer-
cise in itself, and usually occurs after the collection of medical
resources. The decentralization of cost information and a lack of
a research-based “cost-coding dictionary” can make the costing
exercise inaccurate. The ideal cost estimates for each resource use
would be their opportunity cost, deﬁned as the value of that good
or service in its next best use. Opportunity costs are reﬂected as
the price in a perfectly competitivemarketplace. Nomarketplace is
“perfect,” however, and the health care marketplace has many dis-
tinguishing features (e.g., information asymmetries, market dis-
tortions, and cross-subsidies) that make it less perfect than other
markets. Therefore, routinely used prices of health care goods and
services (e.g., charges and reimbursements) are not true opportu-
nity costs. At their best, health care market prices can be viewed as
“proxy” costs, which can be either higher or lower than opportu-
nity costs. Therefore, cost estimates used in economic studies may
be far removed from opportunity costs, and there are methods to
convert certain available prices to better reﬂect costs (e.g., hospital
cost-to-charge ratios; Mushlin et al., 1998). A speciﬁc example is
the costing of pharmaceuticals, when generic pharmaceuticals are
available. In this case in most health economic evaluations generic
prices are used. This may be considered a conservative approach,
as these generic prices do not reﬂect the true opportunity costs
of these pharmaceuticals. On the contrary, these generic prices do
not result from market mechanisms but are due to patent legis-
lation disturbing the self-regulating nature of the market place.
Therefore a cost–effectiveness analysis, where generic pharmaceu-
ticals are available will results in a high cost per QALY, which may
exceed the threshold, whereas a cost–effectiveness analysis based
on real opportunity costs would have resulted in a favorable cost
per QALY and consequently reimbursement.
Finally there remains a debate on the inclusion or exclusion
of future unrelated costs associated with a treatment increasing
survival. These are the medical costs, which may arise during life-
years gained as a result of the treatment, but are not related to the
treatment of the disorder. Although the health economic guide-
lines do not recommend the inclusion of these costs in the health
economic analysis, the debate on this issue continues, because of
the potential high impact of the inclusion of these costs on the
ICER. An example is cardiovascular disease, where prevention of
mortality due to myocardial infarction in a patient, may lead later
to costs of an unrelated disease. For example, a patient surviv-
ing a myocardial infarction may later suffer from cancer with its
associated costs (van Baal et al., 2011).
SUMMARY
Summarizing, the use of cost–effectiveness as ﬁnal criterion in
the reimbursement process for listing of new pharmaceuticals can
be questioned from a scientiﬁc and policy point of view. Although
cost–effectiveness evaluation is not yet the sole criterion in the cur-
rent decision-making process, its weight can already be substantial
in the various health care systems.
It may lead to inappropriate reimbursement decision because
of inaccuracy in the applied methodologies as well as cost
per QALY threshold. Unacceptable differences between West-
European countries, especially discounting and threshold, may
lead to unequal access of new innovative pharmaceuticals.
Apart from the issue what method should be used to assess the
optimum value of cost per QALY, the value of a single aggregated
measure to express all aspects of costs and effectiveness could be
questioned. Instead decision-makers may be provided with a list
of consequences of interventions instead of an ICER. Such a cost
consequence approach would enable decision-makers to tailor the
analysis to their speciﬁc needs.
Finally, it is being argued that cost–effectiveness ratio does not
fully capture all social values. A fundamental limitation of health
economics is the fact that it does not adequately consider social val-
ues outside of efﬁciency. By deﬁnition,HTA“is a multidisciplinary
process that summarizes information about the medical, social,
economic, and ethical issues related to the use of a health technol-
ogy in a systematic, transparent, unbiased, and robust manner.”
The emergence of health economic guidelines for the submis-
sion of economic evidence has brought about more consistency
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and quality. But with respect to social and ethical issues, a sys-
tematic set of principles and processes of assessment have not
emerged. Further, whether or not social values are included in an
HTA appears to be relatively capricious and arbitrary. The need
to advance consideration of social values in HTA and economic
evaluation has long been recognized. Compelling arguments for
economics to recognize the relevance of social values were made
long ago (Williams, 1995; Nord et al., 1999).
Hence the health care community “cannot seem to get out of
the starting blocks when it comes to considering objectives out-
side of cost–effectiveness.” For example, separate budgets may be
required for life-saving products, which are not cost–effective.
Does this all mean that cost–effectiveness should not be used
at all? No, contrary, cost–effectiveness analyses show us how much
health “bang” we get for our “buck,” which is very valuable infor-
mation for health decision-makers, when trying to relate costs
to clinical outcomes. However, a reimbursement decision should
incorporate also other decision criteria, like efﬁcacy and safety of
a new treatment, equity and social values, and impact on health-
related quality of life. Therefore reimbursement decisions would
be better based on a multi criteria process. Cost–effectiveness can
be included,but its weight in the overall decision should be consid-
ered with prudence considering the methodological controversies
and its substantial impact on patients.
REFERENCES
Attema, A. E., and Brouwer, W.
B. (2010). The value of correct-
ing values: inﬂuence and impor-
tance of correcting TTO scores for
time preference. Value Health 13,
879–884.
Brouwer, W. B., Niessen, L. W., Postma,
M. J., and Rutten, F. F. (2005).
Need for differential discounting
of costs and health effects in cost
effectiveness analyses. BMJ 331,
446–448.
Busschbach, J. J. V., and Dewel, G. O.
(2010). Het pakketprincipe kostenef-
fectiviteit achtergrondstudie ten beho-
eve van de “appraisal” fase in
pakketbeheer. Rapport College voor
Zorgverzekeringen. Publicatie num-
mer 291, Diemen, The Netherlands.
Claxton, K., Paulden, M., Gravelle, H.,
Brouwer,W., andCulyer,A. J. (2011).
Discounting and decision making in
the economic evaluation of health-
care technologies. Health Econ. 20,
2–15.
Claxton, K., Sculpher, M., Culyer, A.,
McCabe, C., Briggs, A., Akehurst, R.,
Buxton, M., and Brazier, J. (2006).
Discounting and cost-effectiveness
in NICE – stepping back to sort
out a confusion. Health Econ. 15,
1–4.
Cleemput, I., Van Wilder, P., Vrijens,
F., Huybrechts, M., and Ramaek-
ers, D. (2008). Guidelines for
Pharmacoeconomic Evaluations
in Belgium. Health Technology
Assessment (HTA). Brussels: Health
Care Knowledge Centre (KCE).
KCE Reports 78C (D/2008/10.
273/27).
Cropper, M., Aydede, S., and and
Portney, P. (1992). Rates of time
preference for saving lives.Am. Econ.
Rev. 82, 469–472.
Drummond, M. F., Dubois, D., Garat-
tini, L., Horisberger, B., Jönsson, B.,
Kristiansen, I. S., Le Pen,C., Pinto,C.
G., Poulsen, P. B., Rovira, J., Rutten,
F., von der Schulenburg, M. G., and
Sintonen, H. (1999). Current trends
in the use of pharmacoeconomics
and outcomes research in Europe.
Value Health 2, 323–332.
Gold, M. R., Siegel, J. E., Russell, L.
B., and Weinstein, M. C. (eds).
(1996). Cost-Effectiveness in Health
and Medicine. Oxford: Oxford Uni-
versity Press.
Goossens, M. E., Rutten-van Molken,
M. P., Vlaeyen, J. W., and van der
Linden, S. M. (2000). The cost diary:
a method to measure direct and
indirect costs in cost-effectiveness
research. J. Clin. Epidemiol. 53,
688–695.
Heeg, B. M., Damen, J., Buskens,
E., Caleo, S., de Charro, F., and
van Hout, B. A. (2008). Model-
ling approaches: the case of schiz-
ophrenia. Pharmacoeconomics 26,
633–648.
Joree,M., Brunenberg, D., Nelemans, P.,
Wouters, E., Kuijpers, P., Honig, A.,
Willems, D., de Leeuw, P., Severns, J.,
and Boonen, A. (2010). The impact
of differences in EQ-5D and SF-6D
utility scores on the acceptability of
cost-utility ratios. Value Health 13,
222–229.
Keeler, B., and Weinstein, M. (2005).
Uniform discounting in cost-
effectiveness analysis leads
to fairer government policies.
http://www.bmj.com/content/331/
7514/446.extract/reply#bmj_el_117
024
Mushlin, A. I., Hall, W. J., Zwanziger,
J., Gajary, E., Andrews, M., Mar-
ron, R., Zou, K. H., and Moss, A.
J. (1998). The cost-effectiveness
of automatic implantable car-
diac deﬁbrillators. Circulation 97,
2129–2135.
Nord, E. (1994). The QALY-a measure
of social value rather than individual
utility? Health Econ. 3, 89–93.
Nord, E., Pinto, J. L., Richardson, J.,
Menzel, P., and Ubel, P. (1999).
Incorporating societal concerns for
fairness in numerical valuations of
health programmes. Health Econ. 8,
25–39.
Nuijten, M. J., and Hutton, J. (2002).
Cost-effectiveness analysis of inter-
feron beta in multiple sclerosis:
a Markov process analysis. Value
Health 5, 44–54.
Nuijten, M. J. C. (2003). In Search for
More Conﬁdence in Health Economic
Modelling. Thesis at Erasmus Uni-
versity Rotterdam, The Netherlands.
Parkin, D., McNamee, P., Jacoby, A.,
Miller, P., Thomas, S., and Bates,
D. (1998). A cost-utility analy-
sis of interferon beta for multiple
sclerosis. Health Technol. Assess. 2,
iii54–iii64.
Rabinovich, M., Greenberg, D., and
Shemer, J. (2007). Threshold val-
ues for cost-effectiveness ratio
and public funding of med-
ical technologies. Harefuah 146,
453–458, 500.
van Baal, P. H., Feenstra, T. L., Polder, J.
J., Hoogenveen, R. T., and Brouwer,
W. B. (2011). Economic evaluation
and the postponement of health care
costs. Health Econ. 20, 432–445.
van Lier, A., van Hoek, A. J., Opstel-
ten, W., Boot, H. J., and de Melker,
H. E. (2010). Assessing the poten-
tial effects and cost-effectiveness of
programmatic herpes zoster vacci-
nation of elderly in the Nether-
lands. BMC Health Serv. Res.
10, 237. doi: 10.1186/1472-6963-
10-237
Weinstein, M. C., and Fineberg, H. V.
(1980). Clinical Decision Analysis.
Philadelphia, PA: WB Saunders Co.,
228–265.
Williams, A. (1995). Economics, QALYs
and medical ethics–a health econo-
mist’s perspective. Health Care Anal.
3, 221–226.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential con-
ﬂict of interest.
Received: 23 January 2011; paper pend-
ing published: 09 March 2011; accepted:
29 May 2011; published online: 08 June
2011.
Citation: Nuijten MJC and Dubois
DJ (2011) Cost-utility analysis: current
methodological issues and future per-
spectives. Front. Pharmacol. 2:29. doi:
10.3389/fphar.2011.00029
This article was submitted to Frontiers
in Pharmaceutical Medicine and Out-
comes Research, a specialty of Frontiers
in Pharmacology.
Copyright © 2011 Nuijten and Dubois.
This is an open-access article subject
to a non-exclusive license between the
authors and Frontiers Media SA, which
permits use, distribution and reproduc-
tion in other forums, provided the original
authors and source are credited and other
Frontiers conditions are complied with.
www.frontiersin.org June 2011 | Volume 2 | Article 29 | 5
